Tests JNJ-90301900 with chemoradiation for advanced head and neck cancer
Tests an injected drug with chemotherapy and radiation in adults with head and neck cancer.
Plain-language title generated from the registry record
Registry title: A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Key facts
- Where
- L'Hospitalet de Llobregat, Madrid, and Valencia, SpainSee the 4 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 74 years old?
Source: NCT07219212, who can take part
Where in Spain
- Institut Catala D'oncologiaL'Hospitalet de Llobregat, SpainTaking people
- Hospital General Universitario Gregorio MarañónMadrid, SpainTaking people
- Hospital Universitario Fundación Jiménez DíazMadrid, SpainTaking people
- Hospital Universitario Y Politecnico La FeValencia, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Johnson & Johnson Enterprise Innovation Inc.
- Trial code
- NCT07219212EU 2025-522914-22-00
- Record updated
- 3 November 2026
- Original description
This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).Read full original descriptionShow less
A Study of JNJ-90301900 in Combination With Concurrent Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).
Inclusion: Pathologically (histologically or cytologically) proven diagnosis of HNSCC of the oral cavity, oropharynx (p16 negative), hypopharynx, or supraglottic larynx; Stage III, IVA or IVB according to the 8th Edition of the American Joint Committee on Cancer (AJCC) guidelines; A candidate for definitive concurrent chemoradiation therapy treatment as determined by investigator and per local guidelines; Participants must have at least 1 target lesion (primary tumor or involved lymph node) per RECIST v.1.1; Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1.
Exclusion: Ineligible to receive platinum-based chemotherapy; Suspected or known allergies, hypersensitivity, or intolerance to JNJ-90301900 or its excipients; Primary tumor originating in the nasopharynx, paranasal sinuses, salivary glands, thyroid gland, parathyroid gland, skin, or unknown primary site; Non-squamous histology; Stages 0, I, II, and IVC HNSCC, loco-regionally recurrent HNSCC, or synchronous second primary HNSCC (within 2 months).